background
e
filmarray
respiratori
panel
farp
biofir
diagnost
inc
multiplex
polymeras
chain
reaction
pcr
techniqu
detect
respiratori
virus
bacteri
target
singl
reaction
immunocompromis
host
ich
respiratori
ill
often
undergo
bronchoscopi
bronchoalveolar
lavag
bal
prospect
studi
aim
evalu
yield
concord
np
bal
farp
test
perform
patient
concurr
method
februari
decemb
patient
ich
nonich
enrol
np
swab
bal
sampl
sent
farp
test
result
e
yield
bal
farp
among
ich
nonich
respect
e
yield
posit
np
swab
ich
versu
nonich
e
major
patient
concord
result
np
bal
specimen
ich
patient
posit
bal
farp
major
pathogen
detect
np
swab
conclus
e
farp
may
use
ich
given
high
concord
patient
pathogen
identifi
np
farp
farp
perform
bal
like
yield
result
howev
np
farp
neg
perform
test
bal
sampl
may
increment
yield
e
filmarray
respiratori
panel
farp
biofir
diagnost
salt
lake
citi
ut
multiplex
pcr
assay
rapidli
min
detect
common
respiratori
virus
bacteri
target
singl
reaction
publish
studi
shown
multiplex
pcr
panel
rapid
sensit
compar
routin
cultur
antigen
detect
method
although
multiplex
panel
rapid
accur
high
cost
laboratori
patient
may
limit
use
resourcelimit
set
major
immunocompet
patient
respiratori
symptom
diagnost
test
may
requir
test
complet
usual
done
easili
access
specimen
type
eg
throat
swab
nasopharyng
np
swab
gener
limit
target
pathogen
eg
influenza
viru
howev
patient
immunocompromis
critic
ill
rapid
syndrom
panel
may
benefit
furthermor
patient
persist
progress
symptom
may
requir
extens
diagnost
evalu
includ
bronchoscopi
collect
bronchoalveolar
lavag
bal
fluid
e
util
farp
test
use
np
swab
bal
specimen
collect
immunocompromis
host
ich
investig
group
complet
previou
retrospect
studi
analyz
farp
patient
underw
bronchoscopi
bal
evalu
respiratori
ill
e
result
multiplex
panel
bal
compar
test
np
swab
collect
within
day
bronchoscopi
studi
demonstr
high
concord
farp
complet
np
swab
bal
specimen
howev
prior
studi
limit
fact
np
swab
bal
fluid
collect
differ
time
point
data
analyz
mainli
compar
overal
concord
farp
two
specimen
type
order
extend
prior
observ
sought
prospect
evalu
yield
concord
farp
use
np
swab
bal
fluid
collect
concurr
ich
nonich
comparison
group
studi
approv
mayo
clinic
institut
review
board
februari
decemb
patient
ich
nonich
underw
bronchoscopi
bal
part
routin
clinic
care
enrol
studi
age
rang
year
mean
year
male
immunocompromis
statu
defin
patient
recipi
system
steroid
day
diseasemodifi
agent
eg
inhibitor
tumor
necrosi
factor
chemotherapi
calcineurin
inhibitor
hiv
posit
solid
organ
stem
cell
transplant
recipi
andor
posit
lymphoprolif
myelodysplast
syndrom
tabl
ich
patient
eg
lung
transplant
recipi
undergo
routin
graft
reject
surveil
transbronchi
biopsi
bal
also
includ
analysi
ey
would
also
serv
ich
control
group
determin
whether
farp
test
posit
asymptomat
ich
patient
twentyf
patient
meet
criteria
list
also
includ
part
nonich
comparison
group
ese
patient
undergo
bronchoscopi
bal
rule
infect
consid
immunocompromis
enrol
patient
electron
medic
record
review
follow
inform
obtain
demograph
age
sex
presenc
reason
immunosuppress
microbiolog
test
data
bal
specimen
eg
cultur
pcr
specif
respiratori
ill
eg
cough
wheez
clinic
radiograph
featur
result
microbiolog
studi
eg
routin
cultur
review
result
led
impact
patient
manag
consid
true
pathogen
analyz
e
protocol
collect
test
specimen
approv
institut
review
board
center
patient
provid
inform
consent
subsequ
sedat
prior
bronchoscopi
follow
sedat
wireshaft
bbl
cultureswab
becton
dickinson
franklin
lake
nj
use
sampl
posterior
nasopharynx
per
routin
protocol
subsequ
place
ml
viral
transport
media
remel
lenexa
ks
next
bronchoscopi
bal
perform
ml
aliquot
normal
salin
instil
subsegment
bronchu
correspond
area
radiograph
abnorm
ct
forti
ml
bal
fluid
recov
immedi
return
suction
ml
aliquot
bal
specimen
np
swab
transport
laboratori
store
test
within
hour
test
addit
farp
test
perform
sole
studi
purpos
follow
microbiolog
studi
complet
bal
sampl
part
patient
routin
clinic
care
gram
stain
fungal
smear
acidfast
smear
routin
cultur
bacteri
fungal
viral
mycobacteri
realtim
pcr
influenza
respiratori
syncyti
viru
rsv
pneumocysti
jirovecii
pjp
adenoviru
legionella
spp
e
np
swab
collect
sole
studi
purpos
microbiolog
studi
conduct
sourc
test
np
swab
viral
transport
media
test
filmarray
respiratori
panel
accord
manufactur
instruct
addit
ml
raw
bal
fluid
load
filmarray
pouch
test
filmarray
instrument
biofir
follow
protocol
use
np
swab
statist
analysi
done
use
comparison
proport
onlin
chisquar
calcul
http
wwwmedcalcorgcalccomparisonof
proportionsphp
among
patient
enrol
studi
multiplex
panel
posit
least
one
target
np
specimen
bal
sampl
e
major
tabl
twentyseven
ich
patient
least
one
pathogen
detect
np
swab
pathogen
detect
pair
bal
specimen
e
remain
patient
neg
result
pair
bal
sampl
e
farp
posit
least
one
pathogen
bal
specimen
collect
ich
patient
pathogen
detect
pair
np
swab
sampl
e
remain
patient
neg
result
np
specimen
tabl
comparison
farp
overal
yield
microbiolog
studi
eg
routin
bacteri
fungal
viral
cultur
individu
realtim
pcr
studi
bal
specimen
tabl
ich
group
least
one
microbiolog
studi
includ
farp
posit
bal
sampl
compar
bal
specimen
posit
farp
among
ich
patient
either
posit
np
bal
farp
addit
yield
routin
non
farp
microbiolog
studi
among
ich
patient
neg
farp
result
np
swab
bal
organ
identifi
least
one
routin
microbiolog
test
tabl
nonich
patient
microbiolog
studi
posit
least
one
pathogen
bal
specimen
e
major
patient
neg
filmarray
result
np
bal
sampl
tabl
ich
group
common
indic
bronchoscopi
bal
studi
radiograph
infiltr
chest
imag
n
follow
diagnosi
pneumonia
n
cough
n
sepsi
n
e
result
studi
suggest
farp
may
use
evalu
ich
suspicion
lower
respiratori
tract
infect
yield
test
higher
ich
compar
nonich
patient
p
tabl
twentyseven
ich
patient
posit
np
farp
pathogen
detect
pair
bal
sampl
e
remain
patient
neg
farp
result
bal
fluid
tabl
suggest
pathogen
detect
np
swab
farp
perform
multiplex
assay
bal
fluid
unlik
provid
addit
yield
pathogen
includ
farp
among
ich
group
pathogen
detect
bal
fluid
farp
e
major
patient
pathogen
identifi
np
specimen
neg
farp
result
np
swab
tabl
conclud
farp
neg
np
swab
may
addit
valu
test
bal
fluid
multiplex
assay
note
regardless
farp
result
np
swab
proceed
bronchoscopyb
may
still
indic
ich
patient
suspect
infect
sinc
farp
test
certain
pathogen
eg
aspergillu
spp
pneumocysti
nocardia
spp
mycobacteria
spp
import
caus
diseas
immunosuppress
popul
support
cohort
posit
farp
either
np
bal
sampl
addit
pathogen
detect
routin
microbiolog
studi
case
furthermor
among
patient
neg
farp
result
np
bal
specimen
addit
yield
routin
microbiolog
studi
bal
fluid
case
tabl
e
yield
routin
microbiolog
test
eg
cultur
individu
realtim
pcr
assay
ich
cohort
compar
farp
posit
np
swab
bal
specimen
ese
result
suggest
farp
assay
may
serv
rapid
altern
routin
test
target
includ
multiplex
panel
furthermor
farp
test
may
play
import
role
patient
manag
decis
includ
infect
control
antimicrobi
stewardship
bacteri
pathogen
detect
broadspectrum
coverag
could
modifi
offer
specif
antimicrobi
therapi
contrast
viral
pathogen
detect
bacteri
cultur
remain
neg
may
prudent
discontinu
antibiot
initi
target
antivir
therapi
bronchoscopi
bal
routin
order
ich
patient
institut
studi
show
standard
microbiolog
studi
bal
fluid
yield
cohort
compar
yield
farp
believ
compar
yield
farp
popul
provid
addit
support
noninvas
test
reason
adjunct
bal
test
ich
mani
ich
patient
respiratori
ill
place
empir
broadspectrum
antimicrobi
therapi
bal
collect
confound
yield
bal
cultur
multiplex
molecular
test
howev
may
affect
prior
administr
antibiot
propos
use
conjunct
routin
microbiolog
studi
farp
test
bal
fluid
may
signific
impact
diagnosi
manag
ich
patient
respiratori
ill
convers
farp
appear
less
use
nonich
patient
studi
yield
routin
microbiolog
studi
nonich
patient
higher
ich
patient
versu
resp
howev
farp
show
lower
yield
compar
routin
cultur
nonich
cohort
versu
resp
e
perform
farp
observ
studi
compar
studi
literatur
group
previous
perform
retrospect
review
farp
test
np
bal
sampl
collect
within
one
week
studi
report
farp
posit
np
swab
versu
bal
specimen
e
higher
yield
bal
like
due
fact
patient
radiograph
andor
clinic
indic
bal
includ
hammond
et
al
also
assess
perform
farp
use
np
swab
n
bal
specimen
n
collect
ich
patient
n
importantli
studi
compar
np
swab
bal
fluid
collect
concurr
e
result
suggest
farp
overal
yield
identifi
respiratori
pathogen
compar
convent
method
direct
fluoresc
antibodi
dfa
enzym
immunoassay
viral
cultur
soccal
et
al
assess
detect
respiratori
virus
individu
realtim
pcr
assay
use
np
bal
sampl
collect
concurr
lung
transplant
patient
ey
observ
overal
viral
posit
rate
np
sampl
bal
sampl
ey
also
demonstr
lung
transplant
patient
much
slower
lung
function
recoveri
found
evid
reject
addit
viral
pathogen
detect
provid
import
prognost
inform
e
lower
yield
pcr
bal
specimen
could
explain
inclus
lung
transplant
patient
underw
bronchoscopi
without
necessarili
respiratori
symptom
pulmonari
infiltr
declin
airflow
data
support
notion
without
clinic
radiograph
indic
bal
lower
rate
pathogen
detect
studi
sever
limit
discuss
first
number
np
n
bal
n
sampl
test
posit
farp
rel
low
limit
conclus
made
regard
specif
pathogen
test
second
due
heterogen
radiograph
clinic
find
patient
difficult
identifi
specif
clinic
radiolog
featur
would
prompt
perform
farp
test
bal
fluid
versu
np
swab
alon
despit
limit
first
studi
compar
perform
farp
use
bal
fluid
np
swab
collect
concurr
ich
patient
nonich
comparison
group
farp
perform
conjunct
routin
microbiolog
test
ich
provid
import
diagnost
inform
especi
patient
clinic
manifest
respiratori
ill
data
suggest
cohort
farp
test
initi
perform
np
swab
posit
limit
addit
yield
test
farp
bal
fluid
howev
result
multiplex
assay
neg
np
swab
test
bal
specimen
may
provid
addit
inform
especi
patient
lower
respiratori
tract
diseas
necessari
highlight
farp
cover
caus
respiratori
infect
therefor
routin
microbiolog
test
eg
bacteri
mycobacteri
fungal
cultur
continu
essenti
conclus
respiratori
infect
gener
well
toler
immunocompet
host
seriou
lifethreaten
ich
e
earli
detect
diagnosi
appropri
manag
infect
substanti
impact
clinic
care
outcom
erefor
multiplex
test
may
play
import
role
manag
ich
present
respiratori
symptom
filmarray
respiratori
panel
reagent
purchas
use
collabor
research
grant
fund
suppli
depart
laboratori
medicin
patholog
mayo
clinic
e
author
claim
conflict
interest
relat
product
use
studi
